Literature DB >> 15817339

Preoperative radiotherapy for rectal adenocarcinoma: Which are strong prognostic factors?

Olivier Chapet1, Pascale Romestaing, Francoise Mornex, Jean-Christophe Souquet, Veronique Favrel, Jean-Michel Ardiet, Anne d'Hombres, Jean-Pierre Gerard.   

Abstract

PURPOSE: This retrospective 12-year study evaluated the prognostic value of initial and postoperative staging of rectal tumors. METHODS AND MATERIALS: Between 1985 and 1996, 297 patients were treated with preoperative radiotherapy (39 Gy in 13 fractions) and surgery for Stage T2-T4N0-N1M0 rectal adenocarcinoma. Pretreatment staging included a clinical examination and endorectal ultrasonography (EUS) since 1988. Clinical staging was performed by digital rectal examination and rigid proctoscopy. EUS was performed in 236 patients. Postoperative staging was performed by examination of the pathologic specimen.
RESULTS: The median follow-up was 49 months. The overall 5-year survival rate was 67%, with a local failure rate of 9%. The rate of sphincter preservation was 65%. The clinical examination findings were strong prognostic factor for both cT stage (p < 0.001) and cN stage (p < 0.006) but had poor specificity for cN stage (only 25 lymph nodes detected). In both univariate and multivariate analyses, EUS had a statistically significant prognostic value for uT (p < 0.014) but not for uN (p < 0.47) stage. In contrast, pT and pN stages were strong prognostic factors (p < 0.001 and p < 0.001, respectively).
CONCLUSION: Pretreatment staging, including clinical examination and EUS, seemed accurate enough to present a high prognostic value for the T stage. EUS was insufficient to stage lymph node involvement. Owing to its lack of specificity, uN stage was not a reliable prognostic factor. An improvement in N staging is necessary and essential. Despite downstaging, postoperative staging remained a very strong prognostic factor for both T and N stages.

Entities:  

Mesh:

Year:  2005        PMID: 15817339     DOI: 10.1016/j.ijrobp.2004.08.022

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Diffusion-weighted magnetic resonance imaging for predicting the response of rectal cancer to neoadjuvant concurrent chemoradiation.

Authors:  Gang Cai; Ye Xu; Ji Zhu; Wei-Lie Gu; Shuai Zhang; Xue-Jun Ma; San-Jun Cai; Zhen Zhang
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 2.  Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.

Authors:  Gunther Klautke; Rainer Fietkau
Journal:  Int J Colorectal Dis       Date:  2006-10-28       Impact factor: 2.571

3.  Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy.

Authors:  Andrea Ambrosini-Spaltro; Fabrizio Salvi; Christine M Betts; Giovanni P Frezza; Antonio Piemontese; Pietro Del Prete; Cristina Baldoni; Maria P Foschini; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-12-20       Impact factor: 4.064

4.  Comparison of treatment results between surgery alone, preoperative short-course radiotherapy, or long-course concurrent chemoradiotherapy in locally advanced rectal cancer.

Authors:  Chung-Hung Yeh; Miao-Fen Chen; Chia-Hsuan Lai; Wen-Shih Huang; Steve P Lee; Wen-Cheng Chen
Journal:  Int J Clin Oncol       Date:  2011-09-22       Impact factor: 3.402

5.  Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy?

Authors:  Li-Jen Kuo; Jeng-Fong Chiou; Cheng-Jeng Tai; Chun-Chao Chang; Ching-Huei Kung; Sey-En Lin; Chin-Sheng Hung; Weu Wang; Ka-Wai Tam; Hung-Chia Lee; Hung-Hua Liang; Yu-Jia Chang; Po-Li Wei
Journal:  Int J Colorectal Dis       Date:  2011-11-15       Impact factor: 2.571

6.  Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.

Authors:  Miguel Nogué; Antonieta Salud; Pilar Vicente; Antonio Arriví; José María Roca; Ferran Losa; José Ponce; María José Safont; Inmaculada Guasch; Isabel Moreno; Ana Ruiz; Carles Pericay
Journal:  Oncologist       Date:  2011-04-05

7.  Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer.

Authors:  Kyungyeon Hwang; In Ja Park; Chang Sik Yu; Seok-Byung Lim; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Jin Cheon Kim
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

8.  Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors.

Authors:  Fernando Cabanillas; Mariely Nieves-Plaza; Gerardo Quevedo; Ignacio A Echenique
Journal:  P R Health Sci J       Date:  2012-06       Impact factor: 0.705

9.  Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy.

Authors:  Young Joo Park; Byung Ryul Oh; Sang Woo Lim; Jung Wook Huh; Jae Kyun Joo; Young Jin Kim; Hyeong Rok Kim
Journal:  J Korean Soc Coloproctol       Date:  2010-08-31

10.  Prognostic Significance of Neoadjuvant Rectal Scores in Preoperative Short-Course Radiotherapy and Long-Course Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer.

Authors:  Wen-Shih Huang; Feng-Che Kuan; Meng-Hung Lin; Miao-Fen Chen; Wen-Cheng Chen
Journal:  Ann Surg Oncol       Date:  2020-08-13       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.